Tandem Diabetes Care, Inc. Research and Development Expense
Tandem Diabetes Care, Inc. (TNDM) reported Research and Development Expense of $33.57 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-03
- Tandem Diabetes Care, Inc. research and development expense for the quarter ending 2022-06-30 was $33.57M, a 63.77% increase year-over-year.
- Tandem Diabetes Care, Inc. research and development expense for the quarter ending 2022-03-31 was $33.16M, a 84.62% increase year-over-year.
- Tandem Diabetes Care, Inc. research and development expense for the quarter ending 2021-12-31 was $29.49M, a 69.73% increase year-over-year.
- Tandem Diabetes Care, Inc. research and development expense for the quarter ending 2021-09-30 was $24.10M, a 49.76% increase year-over-year.
- Tandem Diabetes Care, Inc. research and development expense for fiscal 2021 was $92.05M, a 44.80% increase from fiscal 2020.
- Tandem Diabetes Care, Inc. research and development expense for fiscal 2020 was $63.57M, a 40.65% increase from fiscal 2019.
- Tandem Diabetes Care, Inc. research and development expense for fiscal 2019 was $45.20M, a 54.65% increase from fiscal 2018.
- Tandem Diabetes Care, Inc. research and development expense for fiscal 2018 was $29.23M, a 41.46% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2022-06-30 | $33.57M 10-Q · filed 2022-08-03 | $66.73M 10-Q · filed 2022-08-03 | $96.22M derived: sum of 3 quarters · filed 2022-08-03 | $120.33M derived: sum of 4 quarters · filed 2022-08-03 | |||
| 2022-03-31 | $33.16M 10-Q · filed 2022-05-04 | $62.65M derived: sum of 2 quarters · filed 2022-05-04 | $86.75M derived: sum of 3 quarters · filed 2022-05-04 | $107.25M derived: sum of 4 quarters · filed 2022-08-03 | |||
| 2021-12-31 | $29.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $53.59M derived: sum of 2 quarters · filed 2022-02-22 | $74.09M derived: sum of 3 quarters · filed 2022-08-03 | $92.05M 10-K · filed 2022-02-22 | |||
| 2021-09-30 | $24.10M 10-Q · filed 2021-11-03 | $44.60M derived: sum of 2 quarters · filed 2022-08-03 | $62.56M 10-Q · filed 2021-11-03 | $79.94M derived: sum of 4 quarters · filed 2022-08-03 | |||
| 2021-06-30 | $20.50M 10-Q · filed 2022-08-03 | $38.46M 10-Q · filed 2022-08-03 | $55.84M derived: sum of 3 quarters · filed 2022-08-03 | $71.93M derived: sum of 4 quarters · filed 2022-08-03 | |||
| 2021-03-31 | $17.96M 10-Q · filed 2022-05-04 | $35.34M derived: sum of 2 quarters · filed 2022-05-04 | $51.43M derived: sum of 3 quarters · filed 2022-05-04 | $67.42M derived: sum of 4 quarters · filed 2022-05-04 | |||
| 2020-12-31 | $17.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $33.47M derived: sum of 2 quarters · filed 2022-02-22 | $49.46M derived: sum of 3 quarters · filed 2022-02-22 | $63.57M 10-K · filed 2022-02-22 | |||
| 2020-09-30 | $16.09M 10-Q · filed 2021-11-03 | $32.08M derived: sum of 2 quarters · filed 2021-11-03 | $46.20M 10-Q · filed 2021-11-03 | $58.77M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2020-06-30 | $15.99M 10-Q · filed 2021-08-04 | $30.10M 10-Q · filed 2021-08-04 | $42.67M derived: sum of 3 quarters · filed 2022-02-22 | $54.71M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2020-03-31 | $14.12M 10-Q · filed 2021-05-05 | $26.68M derived: sum of 2 quarters · filed 2022-02-22 | $38.72M derived: sum of 3 quarters · filed 2022-02-22 | $49.93M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2019-12-31 | $12.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $24.61M derived: sum of 2 quarters · filed 2022-02-22 | $35.81M derived: sum of 3 quarters · filed 2022-02-22 | $45.20M 10-K · filed 2022-02-22 | |||
| 2019-09-30 | $12.04M 10-Q · filed 2020-11-05 | $23.24M derived: sum of 2 quarters · filed 2020-11-05 | $32.63M 10-Q · filed 2020-11-05 | $41.43M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-06-30 | $11.20M 10-Q · filed 2020-07-30 | $20.59M 10-Q · filed 2020-07-30 | $29.39M derived: sum of 3 quarters · filed 2021-02-24 | $37.39M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-03-31 | $9.39M 10-Q · filed 2020-04-30 | $18.19M derived: sum of 2 quarters · filed 2021-02-24 | $26.18M derived: sum of 3 quarters · filed 2021-02-24 | $32.64M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2018-12-31 | $8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $16.80M derived: sum of 2 quarters · filed 2021-02-24 | $23.25M derived: sum of 3 quarters · filed 2021-02-24 | $29.23M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $8.00M 10-Q · filed 2019-11-04 | $14.46M derived: sum of 2 quarters · filed 2019-11-04 | $20.43M 10-Q · filed 2019-11-04 | $26.18M derived: sum of 4 quarters · filed 2020-02-24 | |||
| 2018-06-30 | $6.46M 10-Q · filed 2019-08-01 | $12.43M 10-Q · filed 2019-08-01 | $18.18M derived: sum of 3 quarters · filed 2020-02-24 | $23.10M derived: sum of 4 quarters · filed 2020-02-24 | |||
| 2018-03-31 | $5.97M 10-Q · filed 2019-04-30 | $11.73M derived: sum of 2 quarters · filed 2020-02-24 | $16.64M derived: sum of 3 quarters · filed 2020-02-24 | $21.51M derived: sum of 4 quarters · filed 2020-02-24 | |||
| 2017-12-31 | $5.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $10.66M derived: sum of 2 quarters · filed 2020-02-24 | $15.53M derived: sum of 3 quarters · filed 2020-02-24 | $20.66M 10-K · filed 2020-02-24 | |||
| 2017-09-30 | $4.91M 10-Q · filed 2018-11-01 | $9.78M derived: sum of 2 quarters · filed 2018-11-01 | $14.91M 10-Q · filed 2018-11-01 | $19.25M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | $4.87M 10-Q · filed 2018-07-30 | $10.00M 10-Q · filed 2018-07-30 | $14.34M derived: sum of 3 quarters · filed 2019-02-26 | $20.50M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | $5.13M 10-Q · filed 2018-04-26 | $9.47M derived: sum of 2 quarters · filed 2019-02-26 | $15.63M derived: sum of 3 quarters · filed 2019-02-26 | $19.77M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $10.50M derived: sum of 2 quarters · filed 2019-02-26 | $14.64M derived: sum of 3 quarters · filed 2019-02-26 | $18.81M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $6.15M 10-Q · filed 2017-10-26 | $10.30M derived: sum of 2 quarters · filed 2017-10-26 | $14.46M 10-Q · filed 2017-10-26 | $18.60M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-06-30 | $4.14M 10-Q · filed 2017-07-27 | $8.31M 10-Q · filed 2017-07-27 | $12.45M derived: sum of 3 quarters · filed 2018-03-01 | $17.54M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-03-31 | $4.17M 10-Q · filed 2017-04-27 | $8.30M derived: sum of 2 quarters · filed 2018-03-01 | $13.40M derived: sum of 3 quarters · filed 2018-03-01 | $17.27M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $9.23M derived: sum of 2 quarters · filed 2018-03-01 | $13.10M derived: sum of 3 quarters · filed 2018-03-01 | $16.96M 10-K · filed 2018-03-01 | |||
| 2015-09-30 | $5.09M 10-Q · filed 2016-11-01 | $8.97M derived: sum of 2 quarters · filed 2016-11-01 | $12.83M 10-Q · filed 2016-11-01 | $16.75M derived: sum of 4 quarters · filed 2017-03-08 | |||
| 2015-06-30 | $3.87M 10-Q · filed 2016-07-28 | $7.74M 10-Q · filed 2016-07-28 | $11.66M derived: sum of 3 quarters · filed 2017-03-08 | $16.16M derived: sum of 4 quarters · filed 2017-03-08 | |||
| 2015-03-31 | $3.86M 10-Q · filed 2016-04-28 | $7.78M derived: sum of 2 quarters · filed 2017-03-08 | $12.29M derived: sum of 3 quarters · filed 2017-03-08 | $15.99M derived: sum of 4 quarters · filed 2017-03-08 | |||
| 2014-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $8.43M derived: sum of 2 quarters · filed 2017-03-08 | $12.13M derived: sum of 3 quarters · filed 2017-03-08 | $15.79M 10-K · filed 2017-03-08 | |||
| 2014-09-30 | $4.51M 10-Q · filed 2015-10-29 | $4.51M 10-Q · filed 2014-11-06 | $8.21M derived: sum of 2 quarters · filed 2015-10-29 | $11.87M 10-Q · filed 2015-10-29 | $11.87M 10-Q · filed 2014-11-06 | $15.22M derived: sum of 4 quarters · filed 2016-02-24 | |
| 2014-06-30 | $3.70M 10-Q · filed 2014-07-31 | $7.36M 10-Q · filed 2015-07-30 | $7.36M 10-Q · filed 2014-07-31 | $10.71M derived: sum of 3 quarters · filed 2016-02-24 | $13.36M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-03-31 | $3.66M 10-Q · filed 2015-04-30 | $3.66M 10-Q · filed 2014-05-06 | $7.01M derived: sum of 2 quarters · filed 2016-02-24 | $9.66M derived: sum of 3 quarters · filed 2016-02-24 | $12.42M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2013-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $6.00M derived: sum of 2 quarters · filed 2016-02-24 | $8.76M derived: sum of 3 quarters · filed 2016-02-24 | $11.08M 10-K · filed 2016-02-24 | |||
| 2013-09-30 | $2.65M 10-Q · filed 2014-11-06 | $5.41M derived: sum of 2 quarters · filed 2014-11-06 | $7.73M 10-Q · filed 2014-11-06 | ||||
| 2013-06-30 | $2.76M 10-Q · filed 2014-07-31 | $5.08M 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | $2.32M 10-Q · filed 2014-05-06 | ||||||
| 2012-12-31 | $9.01M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |